KAYLA FREEMAN: Open Payments
NPI 1891319091 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,126 in 9 payments from 5 companies in 2025. Trend: 2023 $634 · 2024 $868 · 2025 $1,126
Consulting: $660Food & beverage: $466
| Company | Payments | Amount |
|---|---|---|
| Stemline Therapeutics Inc. | 2 | $745 |
| AstraZeneca Pharmaceuticals LP | 3 | $177 |
| Gilead Sciences, Inc. | 2 | $156 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| TG Therapeutics, Inc. | 1 | $24 |
Products named: Orserdu, Trodelvy, AMVUTTRA, BRIUMVI.
Industry payments across GA — which companies pay providers there.
